Dabigatran is an oral direct thrombin inhibitor, touted as non-inferior to Warfarin (though there is some debate about its safety (Yao, Abraham et al. 2016, Hernandez, Baik et al. 2018).
Read More
Dabigatran is an oral direct thrombin inhibitor, touted as non-inferior to Warfarin (though there is some debate about its safety (Yao, Abraham et al. 2016, Hernandez, Baik et al. 2018).
Read More
Dabigatran Site of Action (www.medscape.com)
The burdens associated with the use of traditional anticoagulants such as subcutaneous heparins and oral vitamin K antagonists (VKAs) have spurred the popularity of non-vitamin K oral anticoagulants (NOACs) for stroke prevention in patients with nonvalvular atrial fibrillation and for the prevention and treatment of venous thromboembolism.
Read More